Merck to buy Cubist Pharmaceuticals for $8.4 billion

Merck says it agreed to buy Cubist Pharmaceuticals for $8.4 billion, and the assumptions of $1.1 billion in debt, as it continues with the strategy to narrow its focus on diabetes, acute hospital care, vaccines and oncology.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.